Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600743 · ClinicalTrials.gov registry record · Phase 2
Effect of a CCK-1R Agonist on Food Intake in Humans
A Phase 2 study, sponsored by St. Luke's-Roosevelt Hospital Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00600743 is a Phase 2 study that was terminated before completion, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 40 participants.
The verdict
NCT00600743, a Phase 2 study, was terminated before completion, sponsored by St. Luke's-Roosevelt Hospital Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The ultimate aim of this study is to test the hypothesis that the oral cholecystokinin (CCK) agonist GSKI181771X will reduce the size of a binge meal among individuals with Bulimia Nervosa. The study will be conducted in phases. First, an effective dose for reducing food intake, when normal subjects eat normally will be attained. Next, it will be determined whether intake at this dose is reduced in control subjects instructed to eat to capacity. If the dose is still effective compared to placebo, the same dose will be tested in patients with bulimia nervosa.
Interventions
- DRUG Placebo
- DRUG GSKI181771X (CCK-1R agonist)
- BEHAVIORAL Instructions to binge eat
- BEHAVIORAL Instructions to eat normally
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00600743
The ClinicalTrials.gov registry entry for NCT00600743 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Luke's-Roosevelt Hospital Center, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00600743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00600743 about?
NCT00600743 is a clinical study titled "Effect of a CCK-1R Agonist on Food Intake in Humans". The ultimate aim of this study is to test the hypothesis that the oral cholecystokinin (CCK) agonist GSKI181771X will reduce the size of a binge meal among individuals with Bulimia Nervosa. The study will be conducted in phases. First, an effective dose for reducing food intake, when normal subjects...
What is the current status of trial NCT00600743?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-01. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00600743?
The interventions under investigation include: Placebo (DRUG), GSKI181771X (CCK-1R agonist) (DRUG), Instructions to binge eat (BEHAVIORAL), Instructions to eat normally (BEHAVIORAL).
Who is sponsoring clinical trial NCT00600743?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.